Neuphoria Therapeutics (B1N0) Financial Statements
Neuphoria Therapeutics Financial Overview
Neuphoria Therapeutics's market cap is currently $14.73M. The company's EPS TTM is $-7.26; its P/E ratio is -0.42; Neuphoria Therapeutics is scheduled to report earnings on August 23, 2023, and the estimated EPS forecast is $-0.98. See an overview of income statement, balance sheet, and cash flow financials.
| Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.17M | $ 15.65M | $ 0.00 | $ 0.00 | $ 383.16K |
| Gross Profit | $ 511.21K | $ 14.99M | $ -662.99K | $ -671.48K | $ -9.98M |
| Operating Income | $ -9.81M | $ -1.13M | $ -26.79M | $ -33.09M | $ -31.02M |
| EBITDA | $ -9.15M | $ -466.20K | $ -25.98M | $ -31.48M | $ -30.75M |
| Net Income | $ -13.45M | $ -369.63K | $ -15.49M | $ -32.18M | $ -22.94M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 19.87B | $ 21.59M | $ 12.61M | $ 8.06M | $ 33.56M |
| Total Assets | $ 28.71B | $ 43.44M | $ 27.65M | $ 19.39M | $ 65.30M |
| Total Debt | $ 34.34K | $ 226.49K | $ 272.74K | $ 582.35K | $ 693.55K |
| Net Debt | $ -19.87B | $ -21.37M | $ -12.34M | $ -7.80M | $ -32.87M |
| Total Liabilities | $ 4.11B | $ 14.57M | $ 10.16M | $ 4.74M | $ 8.40M |
| Stockholders' Equity | $ 24.60B | $ 28.87M | $ 17.49M | $ 14.65M | $ 56.91M |
| Cash Flow | |||||
| Free Cash Flow | $ -12.35B | $ 77.23M | $ -14.68M | $ -9.85M | $ -21.75M |
| Operating Cash Flow | $ -12.35B | $ 77.23M | $ -14.68M | $ -9.85M | $ -21.75M |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 621.64K |
| Financing Cash Flow | $ 17.92B | $ 1.53B | $ 15.11M | $ 5.81M | $ 26.99M |
Currency in AUD